Literature DB >> 18751982

Anti-cyclic citrullinated peptide antibody is associated with radiographic erosion in rheumatoid arthritis independently of shared epitope status.

Churl Hyun Im1, Eun Ha Kang, Hee Jung Ryu, Jung Hwa Lee, Eun Young Lee, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song.   

Abstract

Shared epitope (SE) and anti-cyclic citrullinated peptide (CCP) antibody are known to be associated with rheumatoid arthritis (RA). The authors investigated their adjusted effects on RA from Korean population. Clinical features were evaluated in 226 RA patients; 164 healthy controls were enrolled. HLA-DRB1 typing for SE was done by polymerase chain reaction. Anti-CCP antibody levels were determined by enzyme linked immunosorbent assay. Logistic regression analysis method was used for adjusted effects. SE and anti-CCP antibody were associated with RA susceptibility. Anti-CCP antibody was associated with RA susceptibility independent of SE [odds ratio, OR 179.9 (95% confidence interval, CI 40.8-792.2), P < 0.001]. Anti-CCP antibody was associated with radiographic erosive changes independent of SE or rheumatoid factor [OR 3.9 (95% CI 1.1-13.3), P = 0.032]. Anti-CCP antibody was strongly associated with RA susceptibility and radiographic erosion of RA patients, independent of SE in Korean.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751982     DOI: 10.1007/s00296-008-0690-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis.

Authors:  S Kaltenhäuser; M Pierer; S Arnold; M Kamprad; C Baerwald; H Häntzschel; U Wagner
Journal:  Rheumatology (Oxford)       Date:  2006-05-25       Impact factor: 7.580

2.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

3.  Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles.

Authors:  Inmaculada Del Rincón; Daniel F Battafarano; Ramón A Arroyo; Frederick T Murphy; Michael Fischbach; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-04-15

4.  The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; Tom W J Huizinga; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2006-04

5.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

Review 6.  Clinical epidemiology: diagnostic and prognostic tests.

Authors:  Michael M Ward
Journal:  Curr Opin Rheumatol       Date:  2003-03       Impact factor: 5.006

7.  Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.

Authors:  Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Authors:  F A van Gaalen; S P Linn-Rasker; W J van Venrooij; B A de Jong; F C Breedveld; C L Verweij; R E M Toes; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2004-03

Review 9.  Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value.

Authors:  Martinus A M van Boekel; Erik R Vossenaar; Frank H J van den Hoogen; Walther J van Venrooij
Journal:  Arthritis Res       Date:  2001-11-06

10.  A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.

Authors:  Ewa Berglin; Leonid Padyukov; Ulf Sundin; Göran Hallmans; Hans Stenlund; Walther J Van Venrooij; Lars Klareskog; Solbritt Rantapää Dahlqvist
Journal:  Arthritis Res Ther       Date:  2004-05-11       Impact factor: 5.156

View more
  6 in total

1.  The influence of polygenic risk scores on heritability of anti-CCP level in RA.

Authors:  J Cui; K E Taylor; Y C Lee; H Källberg; M E Weinblatt; J S Coblyn; L Klareskog; L A Criswell; P K Gregersen; N A Shadick; R M Plenge; E W Karlson
Journal:  Genes Immun       Date:  2014-01-02       Impact factor: 2.676

2.  Periodontitis is associated with rheumatoid arthritis: a study with longstanding rheumatoid arthritis patients in Korea.

Authors:  In Ah Choi; Jin-Hee Kim; Yong Mi Kim; Joo Youn Lee; Kyung Hwa Kim; Eun Young Lee; Eun Bong Lee; Yong-Moo Lee; Yeong Wook Song
Journal:  Korean J Intern Med       Date:  2016-03-25       Impact factor: 2.884

3.  Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.

Authors:  Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2020-06-10       Impact factor: 5.156

Review 4.  Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies.

Authors:  Y W Song; E H Kang
Journal:  QJM       Date:  2009-11-19

5.  Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case-control study.

Authors:  Jing Li; Honghua Wu; Xinxiang Huang; Dong Xu; Wenjie Zheng; Yan Zhao; Wanli Liu; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

6.  Increased expression of CXCL2 in ACPA-positive rheumatoid arthritis and its role in osteoclastogenesis.

Authors:  X Wang; L Sun; N He; Z An; R Yu; C Li; Y Li; Y Li; X Liu; X Fang; J Zhao
Journal:  Clin Exp Immunol       Date:  2020-10-21       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.